Parion Sciences, Inc.

Merck Sharp + Dohme Corp.

Albany Molecular Research, Inc.

Bruce Sargent

Jianzhong Zhang

Michael Ross Johnson

Bruce Francis Molino

Ravi P Nargund

Peter Guzzo

Shuwen He

Jian Liu

Iyassu Sebhat

Linus S Lin

Alan John Henderson

Christopher L Franklin

Mark Hadden

Tianying Jian

Allan James Goodman

Cheng Guo

Larry Yet

Peter H Dobbelaar

Megan Ruenz

Provided is a method of treating cystic fibrosis in which an effective amount of a compound represented by formula (I) is administered to a subject in need thereof: where the structural variables are as defined herein.

Capped pyrazinoylguanidine sodium channel blockers

Provided are compounds represented by the formula: where the structural variables are as defined herein. The compounds function as sodium channel blockers and my be used for promoting hydration of mucosal surfaces.

The present application relates to pyrazinoyl guanidine sodium channel blockers having the structure: or a pharmaceutically acceptable salt thereof, where the structural variables are as defined herein. The present invention also relates pharmaceutical compositions comprising the sodium channel blockers and their use in methods of treatment, including the treatment of cardiovascular disease, cystic fibrosis, and chronic bronchitis and in the rehydration of mucosal surfaces and promotion of mucus clearance in a patient.

Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.

Substituted imidazoles as bombesin receptor subtype-3 modulators

The invention relates to substituted pyrazinoylguanidine compounds. These compounds are useful as sodium channel blockers, and may be effective in treating a variety of conditions including chronic bronchitis and cystic fibrosis.

The present invention relates to group of pyrazinoylguanidine compounds useful as sodium channel blockers. The compounds may be used to promote promoting hydration of mucosal surfaces.

The present invention relates to compounds represented by formula (I): where the structural variables are as defined herein. The compounds are useful for promoting hydration of mucosal surfaces.

The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.

The present invention relates to a compound represented by formula (I): where the structural variables are as defined herein. The compound is useful for promoting hydration of mucosal surfaces.

Compounds are provided which are represented by the formula: where the structural variables are defined herein. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.

Growing community of inventors

Delmar, NY, United States of America

Bruce Sargent